Clinical significance of the De Ritis ratio for detecting prostate cancer in a repeat prostate biopsy

Investig Clin Urol. 2019 Nov;60(6):447-453. doi: 10.4111/icu.2019.60.6.447. Epub 2019 Sep 9.

Abstract

Purpose: We evaluated factors predicting a positive repeat biopsy result in patients with an initial negative prostate biopsy result.

Materials and methods: This study included 124 patients in whom prostate cancer (PCa) was not detected in the initial transrectal ultrasound-guided prostate biopsy and who underwent repeat biopsy from January 2011 to December 2017. Patients without PCa in both initial and repeat prostate biopsies were designated as group 1 (n=82), and those in whom PCa was detected on a repeat prostate biopsy were designated as group 2 (n=42). Among group 2 patients, 6 had insignificant PCa according to the Epstein criteria and were combined with group 1 patients to make up group A (n=88). Patients with significant PCa were categorized as group B (n=36). We compared clinicopathologic characteristics between the groups.

Results: Multivariate analysis showed that age (p=0.018) and detection of atypical small acinar proliferation (ASAP) or ≥3 cores of high-grade prostatic intraepithelial neoplasia (HGPIN) (p=0.011) on the initial biopsy were predictive factors for a positive result on a repeat biopsy. When we compared group A and group B, age (p=0.004) and the De Ritis ratio (p=0.024) were significantly higher in group B in the multivariate analysis.

Conclusions: Age and the detection of ASAP or ≥3 cores of HGPIN on the initial biopsy were associated with detection of PCa on a repeat biopsy. Age and the De Ritis ratio were found to be predictive factors for the detection of clinically significant PCa on a repeat biopsy.

Keywords: Biopsy; Prostatic neoplasms; Transaminases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alanine Transaminase / blood*
  • Aspartate Aminotransferases / blood*
  • Biopsy
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / pathology*
  • Retrospective Studies

Substances

  • Aspartate Aminotransferases
  • Alanine Transaminase